OncoMatch/Clinical Trials/NCT06799065
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Is NCT06799065 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ATX-295 for advanced solid tumors.
Treatment: ATX-295 — The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Ovarian Cancer
Triple-Negative Breast Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Clinically significant (ie, active) or uncontrolled cardiovascular disease [excluded]
Clinically significant (ie, active) or uncontrolled cardiovascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- SCRI Oncology Partners · Nashville, Tennessee
- MD Anderson Cancer Center · Houston, Texas
- NEXT Oncology · San Antonio, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify